Franklin Stuart Friedman - 17 Jan 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
+$50,000
Form type
4
Filing time
19 Jan 2023, 15:06:15 UTC
Previous filing
24 Jun 2022
Next filing
12 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $50,000 +3,269 $15.30 3,269 17 Jan 2023 Common Stock 3,269 $21.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.